Therapeutic benefit of PDE4 inhibitors in inflammatory diseases

Current Opinion in Investigational Drugs

Volumn 8, Issue 5, 2007, Pages 364-372

  Dastidar, Sunanda G ^a   Rajagopal, Deepa ^a   Ray, Abhijit ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Arthritis; cAMP; Inflammation; Inflammatory bowel disease; Inhibition; PDE4

Indexed keywords

1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; 2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 9 (2 HYDROXY 3 NONYL)ADENINE; AROFYLLINE; BAY 656207; BAY 736691; BUDESONIDE; C 3885; CC 10004; CC 1088; CC 11050; CC 7085; CERTOLIZUMAB PEGOL; CILOMILAST; CILOSTAMIDE; EHT 0202; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; IPL 455903; KW 4490; LAS 37779; MEM 1414; MILRINONE; MN 001; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; ND 125; NIMODIPINE; ONO 6126; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; ROFLUMILAST; ROLIPRAM; SILDENAFIL; TETOMILAST; UNCLASSIFIED DRUG; ZAPRINAST;

ALLERGIC RHINITIS; ALZHEIMER DISEASE; ARTHRITIS; ASTHMA; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENTERITIS; FEASIBILITY STUDY; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; LUNG DYSPLASIA; MUSCLE ATROPHY; NAUSEA; OSTEOARTHRITIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SKIN INFLAMMATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VASCULITIS; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS; ASTHMA; CYCLIC AMP; DERMATITIS, ATOPIC; DRUGS, INVESTIGATIONAL; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; PHOSPHODIESTERASE INHIBITORS; PSORIASIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIGNAL TRANSDUCTION;

EID: 34247889972     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Baillie GS, Scott JD, Houslay MD: Compartmentalisation of phosphodiesterases and protein kinase A: Opposites attract. FEBS Lett (2005) 579(15):3264-3270.
2. Baillie GS, Houslay MD: Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr Opin Cell Biol (2005) 17(2):129-134.
3. Houslay MD: Adaption in cAMP signalling processes: A central role in cyclic AMP phosphodiesterases. Semin Cell Dev Biol (1998) 9(2):161-167.
4. Houslay MD, Milligan G: Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci (1997) 22(6):217-224.
5. Beavo JA: Cyclic nucleotide phosphodiesterase: Functional implications of multiple isoforms. Physiol Rev (1995) 75(4):725-748.
6. Giembycz M: PDE4D-deficient mice knock the breath out of asthma. Trends Pharmacol Sci (2000) 21(8):291-292.
7. Wollin L, Bundschuh DS, Wohlsen A, Marx D, Beume R: Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulm Pharmacol Ther (2006) 19(5):343-352.
8. Soto FJ, Hanania NA: Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med (2005) 11(2):129-134.
9. Barnette MS: Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog Drug Res (1999) 53:193-229.
10. Mehmedagic A, Vranic E, Hadzovic S, Pokrajac M, Milic J, Mehic B, Zutic H, Konjicija A: The new trends in theophylline therapy. Bosn J Basic Med Sci (2002) 2(1-2):62-65.
11. Giembycz MA, Dent G, Souness JE: Theophyline and isoenzyme selective phosphodiesterase inhibitors. In: Allergy & Allergic Diseases. Kay AB (Ed), Blackwell Scientific, London, UK (1997):531-567.
12. Lipworth BJ: Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet (2005) 365(9454):167- 175.
13. Souness JE, Aldous D, Sargent C: Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacol (2000) 47(2-3):127-162.
14. Giembycz MA: Development status of second generation PDE4 inhibitors for asthma and COPD: The story so far. Monaldi Arch Chest Dis (2002) 57(1):48-64. •• This comprehensive review describes the development of PDE4 inhibitors, and discusses the concept of selective targeting of PDE4 subtypes and combination therapy as a strategy to improve the potency and therapeutic index of inhibitors.
15. Torphy TT, Compton CH, Marks MJ, Sturton G: Phosphodiesterase 4 inhibitors. In: New Drugs for Asthma, Allergy and COPD. Prog Respir Res. Hansel TT, Barnes PJ (Eds), S Karger AG, Basel, Switzerland (2001) 31:321-325.
16. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD: Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial. Lancet (2005) 366(9485):563-571.
17. Jeffery P: Phosphodiesterase 4-selective inhibition: Novel therapy for the inflammation of COPD. Pulm Pharmacol Ther (2005) 18(1):9-17.
18. Marcinkiewicz, J, Grabowska A, Lauterbach R, Bobek M: Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages. Immunopharmacology (2000) 49(3):335-343.
19. Lauterbach R, Szymura-Oleksiak J: Nebulized pentoxifylline in successful treatment of five premature neonates with bronchopulmonary dysplasia. Eur J Pediatr (1999) 158(7):607.
20. Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M: Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: A placebo-controlled, double-blind trial. Crit Care Med (1999) 27(4):807-814.
21. Sanz MJ, Cortijo J, Morcillo EJ: PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther (2005) 106(3):269-297.
22. Blease K, Burke-Gaffney A, Hellewell PG: Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol (1998) 124(1):229-237.
23. Tamir A, Isakov N: Cyclic AMP inhibits phosphatidylinositol-coupled and -uncoupled mitogenic signals in T lymphocytes. Evidence that cAMP alters PKC-induced transcription regulation of members of the jun and fos family of genes. J Immunol (1994) 152(7):3391-3399.
24. Heijink IH, Kauffman HF, Postma DS, de Monchy JG, Vellenga E: Sensitivity of IL-5 production to the cAMP-dependent pathway in human T cells is reduced by exogenous IL-2 in a phosphoinositide 3-kinase-dependent way. Eur J Immunol (2003) 33(8):2206-2215.
25. Kanda N, Watanabe S: Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. Biochem Pharmacol (2001) 62(4):495-507.
26. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K: Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal (2002) 14(1):1-9.
27. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG: Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of NF-κB, P38 MAP kinase and JNK activation. J Pharmacol Exp Ther (2005) 315(3):1188-1195.
28. Vang T, Abrahamsen H, Myklebust S, Horejsi V, Tasken K: Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase A inhibits T cell receptor signaling. J Biol Chem (2003) 278(20):17597- 17600.
29. Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skalhegg BS, Hansson V, Mustelin T, Tasken K: Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med (2001) 193(4):497-507.
30. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A, Mustelin T, Zaccolo M, Houslay M, Tasken K: TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol (2004) 173(8):4847-4858.
31. Yamaki K, Li X, Uchida H, Alam AH, Hossain MA, Yanagisawa R, Takano H, Taneda S, Hayashi H, Mori Y, Yoshino S: Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice. J Pharm Pharmacol (2004) 56(7):877-882.
32. Hatzelmann A, Schudt C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther (2001) 297(1):267-279.
33. Silva PMR, Alves AC, Serra MF, Lucia A, Pires A, Silva JP, Barreto EO, Corderio RSB, Jose PJ, Teixeria MM, Lagnette V, Martins MA: Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme. Br J Pharmacol (2001) 134(2):283-294.
34. Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C: In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4- yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther (2003) 307(1):373-385.
35. Claveau D, Chen SL, O'Keefe S, Zaller DM, Styhler A, Liu S, Huang Z, Nicholson DW, Mancini JA: Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4- bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl) -phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther (2004) 310(2):752-760.
36. Bielekova B, Lincoln A, McFarland H, Martin R: Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol (2000) 164(2):1117-1124.
37. van Schalkwyk E, Strydom K, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbroker D, Bardin PG: Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol (2005) 116(2):292-298.
38. GlaxoSmithKline plc: GSK: Annual report 2006. Annual Report (2007): March 02.
39. ALTANA AG: Altana and Pharmacia in roflumilast deal. Press Release (2002): 22 April.
40. GlaxoSmithKline plc: GlaxoSmithKline receives FDA approvable letter for Ariflo (cilomilast) tablets 15 mg. Press Release (2003): October 27.
41. Tanabe Seiyaku Co Ltd: Building Bridges to Long-Term Growth. Annual Report (2005).
42. Giembycz MA: Life after PDE4: Overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol (2005) 5(3):238-244. •• The advantages of dual PDE inhibitors are described.
43. Odingo JO: Inhibitors of PDE4: A review of recent patent literature. Expert Opin Ther Pat (2005) 15(7):773-787. •• An overview of patents covering PDE4 inhibitors with special focus on clinical developments since 2002 is provided, and PDE4 inhibitors are discussed from a medicinal chemistry perspective.
44. Houslay MD, Schafer P, Zhang KYJ: Phosphodiesterase-4 as a therapeutic target. Drug Disc Today (2005) 10(22):1503-1519. •• An overview of PDE4 inhibitors is provided, and the cellular and molecular biology of PDE4 isoforms are discussed.
45. Zhang KYJ, Ibrahim PN, Gillette S, Bollag G: Phosphodiesterase-4 as a potential drug target. Expert Opin Ther Targets (2005) 9(6):1283-1305. •• This review describes the fundamental biological role of PDE4 in intracellular signaling, as well as its distribution and regulation in tissue.
46. Fan Chung K: Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol (2006) 533(1-3):110-117. •• An excellent review describing the potential of PDE4 inhibitors in airway diseases.
47. Lagente V, Martin-Chouly C, Boichot E, Martins MA, Silva PMR: Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem Inst Oswaldo Cruz (2005) 100(Suppl 1):131-136.
48. Chen Q, Wei W: New therapeutic approaches for rheumatoid arthritis. Assay Drug Dev Technol (2005) 3(3):329-337.
49. Haringman JJ, Oostendorp RL, Tak PP: Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis. Expert Opin Emerg Drugs (2005) 10(2):299-310.
50. Probert L, Plows D, Kontogeorgos G, Kollias G: The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol (1995) 25(6):1794-1797.
51. van den Berg WB, Bresnihan B: Pathogenesis of joint damage in rheumatoid arthritis: Evidence of a dominant role for interleukin-I. Baillieres Best Pract Res Clin Rheumatol (1999) 13(4):577-597.
52. Douni E, Akassoglou K, Alexopoulou L, Georgopoulos S, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, Probert L, Kollias G: Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J Inflamm (1995) 47(1-2):27-38.
53. Macias I, Garcia-Perez S, Ruiz-Tudela M, Medina F, Chozas N, Giron-Gonzalez JA: Modification of pro- and anti-inflammatory cytokines and vascular-related molecules by tumor necrosis factor-α blockade in patients with rheumatoid arthritis. J Rheumatol (2005) 32(11):2102- 2108.
54. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB: IL-1α β-blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol (1999) 163(9):5049- 5055.
55. Butler DM, Malfait AM, Mason LJ, Warden PJ, Kollias G, Maini RN, Feldmann M, Brennan FM: DBA/1 mice expressing the human TNF-α transgene develop a severe, erosive arthritis: Characterization of the cytokine cascade and cellular composition. J Immunol (1997) 159(6):2867-2876.
56. Edwards CJ: Immunological therapies for rheumatoid arthritis. Br Med Bull (2005) 73-74(1):71-82.
57. Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P: Autoimmunity and anti-TNF-α agents. Ann NY Acad Sci (2005) 1051:559-569.
58. Takeba Y, Suzuki N, Wakisaka S, Takeno M, Kaneko A, Asai T, Sakane T: Involvement of cAMP responsive element binding protein (CREB) in the synovial cell hyperfunction in patients with rheumatoid arthritis. Clin Exp Rheumatol (2000) 18(1):47-55.
59. Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfait AM, Maini RN, Feldmann M: Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol (1997) 159(12):6253-6259.
60. Tenor H, Hedbom E, Hauselmann HJ, Schudt C, Hatzelmann A: Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes - functional importance of phosphodiesterase 4. Br J Pharmacol (2002) 135(3):609-618.
61. Meiji Seika Kaisha Ltd: Drug development pipeline: Rolipram. Company Communication (2000): July 06.
62. Aventis Pasteur SA: Drug development pipeline: Piclamilast. Company Communication (2002): April 24.
63. Third International Conference on Cyclic Nucleotide Phosphodiesterases: From genes to therapies, Glasgow, Scotland, UK. IDdb Meeting Report (1996): July 18-21.
64. Freeman HJ (Ed): Inflammatory Bowel Disease. CRC Press, Boca Raton, FL, USA (1989): 1.
65. Lashner BA: Inflammatory bowel disease. The Cleveland Clinic Foundation, Cleveland, OH, USA (2004). http://www.clevelandclinicmeded.com/ diseasemanagement/gastro/inflammatory_bowel/inflammatory_bowel.htm
66. Cominelli F: Cytokine-based therapies for Crohn's disease ? new paradigms. N Eng J Med (2004) 351(20):2045-2048.
67. Johnson & Johnson: Remicade (infliximab) eight-week dosing shown effective in maintaining fistula closures in Crohn's patients. Press Release (2004): February 26.
68. UCB SA: UCB submits biologics license application to FDA for new treatment in Crohn's disease. Press Release (2006): March 02.
69. UCB SA: UCB submits marketing authorisation application in Europe for CIMZIATM, a new Crohn's disease therapy. Press Release (2006): April 28.
70. Banner KH, Trevethick MA: PDE4 inhibition: A novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci (2004) 25(8):430-436.
71. Kohyama T, Liu X, Zhu YK, Wen FQ, Wang HJ, Fang Q, Kobayashi T, Rennard SI: Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-α and neutrophil elastase. Am J Respir Cell Mol Biol (2002) 27(4):487-494.
72. Otsuka Pharmaceutical Co Ltd: Otsuka's ulcerative colitis compound enters phase III trials. Press Release (2003): July 23.
73. Celgene Corp: Celgene Corporation launches clinical trials for new class of TNF-α inhibitors. Press Release (1997): September 29.
74. Celgene Corp: Development pipeline: CC-1088. Company Communication (2005): April 08.
75. Lowes MA, Bowcock AM, Krueger JG: Pathogenesis and therapy of psoriasis. Nature (2007) 445(7130):866-873.
76. Kincaid L: Psoriasis: TNF-α inhibitors and beyond. Drug Disc Today (2005) 10(13):884-886.
77. Chujor SNC, Hammerschmid F, Lam C: Cyclic nucleotide phosphodiesterase 4 subtypes are differentially expressed by primary keratinocytes and human epidermoid cell lines. J Invest Dermatol (1998) 110(3):287- 291.
78. Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M: Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets (2007) 6(1):17-26.
79. Baumer W, Gorr G, Hoppmann J, Ehinger AM, Rundfeldt C, Kietzmann M: AWD-12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis. J Pharm Pharmacol (2003) 55(8):1107-1114.
80. Hoppmann J, Baumer W, Galetzka C, Hofgen N, Kietzmann M, Rundfeldt C. The phosphodiesterase 4 inhibitor AWD-12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol (2005) 57(12):1609-1617.
81. elbion AG: Drug development pipeline: AWD-12-281. Company Communication (2006): July 11.
82. Ghavami A, Hirst WD, Novak TJ: Selective phosphodiesterase (PDE)-4 inhibitors: A novel approach to treating memory deficit? Drugs R&D (2006) 7(2):63-71.
83. Hinkle RT, Dolan E, Cody DB, Bauer MB, Isfort RJ: Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy. Muscle Nerve (2005) 32(6):775-781.
84. Wang D, Wang T: Novel approaches to using PDE4 inhibitors for antihypertensive therapy. Curr Opin Investig Drugs (2005) 6(3):283-288.
85. Dal Piaz V, Giovannoni MP: Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur J Med Chem (2000) 35(5):463-480.
86. Mecklenburg L, Heuser A, Juengling T, Kohler M, Foell R, Ockert D, Tuch K, Bode G: Mesenteritis precedes vasculitis in the rat mesentery after subacute administration of a phosphodiesterase type 4 inhibitor. Toxicol Lett (2006) 163(1):54-64.
87. Robichaud A, Tattersall, FD, Choudhury I, Rodger IW: Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDEIV) in the ferret. Neuropharmacology (1999) 38(2):289-297.
88. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC: PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology (2001) 40(2):262-269.
89. 3H]rolipram binding. Biochem Pharmacol (1996) 51(7):949-956.
90. Souness JE, Rao S: Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal (1997) 9(3-4):227-236.
91. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM: Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol (1999) 56(1):170-174.
92. Jin SL, Lan L, Zoudilova M, Conti M: Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol (2005) 175(3):1523-1531. • This paper describes the direct involvement of PDE4B in inflammation. Data from knockout mice led to strategies targeting PDE4B in anti-inflammatory therapy.
93. Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, Conti M: PDE4D plays a critical role in the control of airway smooth muscle contraction. FASEB J (2003) 17(13):1831-1841. • This study demonstrated the direct involvement of PDE4D in smooth-muscle contraction.
94. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, Jin SL, Conti M: Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol (2004) 173(12):7531-7538.
95. 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest (2002) 110(7):1045-1052. • A mouse anesthesia model is described as a surrogate for emesis which may be used to study the emetic potential of compounds early in drug development.
96. Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL, Conti M, Marks AR: Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell (2005) 123(1):25-35.
97. Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, Giembycz MA: Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol (2003) 284(2):L279-L289.
98. Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE: Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res (2002) 90(2):151-157.
99. Yamamoto S, Sugahara S, Naito R, Ichikawa A, Ikeda K, Yamada T, Shimizu Y: The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo. Eur J Pharmacol (2006) 541(1-2):106- 114.
100. Yamamoto S, Sugahara S, Ikeda K, Yasuaki S: Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models. Eur J Pharmacol (2006) 550(1-3):166-172.
101. Giembycz MA: Phosphodiesterase-4: Selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc (2005) 2(4):326-333. •• The advantages of dual PDE inhibitors in improving the therapeutic index compared with single PDE inhibition is discussed.